Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis

Eosinophilic Granulomatosis with Polyangiitis Successfully Treated with Benralizumab.

(2020) María Vanessa Chica-Guzmán et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma

(2020) Corrado Pelaia et al.   BIOMEDICINE & PHARMACOTHERAPY

Rapid Onset of Effect of Benralizumab on Morning Peak Expiratory Flow in Severe, Uncontrolled Asthma

(2019) Geoffrey Chupp et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Eosinophils from Physiology to Disease: A Comprehensive Review

(2018) Giuseppe A. Ramirez et al.   Biomed Research International

Eosinophilic Lung Diseases

(2016) Vincent Cottin   CLINICS IN CHEST MEDICINE

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

(2016) J Mark FitzGerald et al.   LANCET

A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma

(2015) Richard M. Nowak et al.   AMERICAN JOURNAL OF EMERGENCY MEDICINE

MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function

(2010) Roland Kolbeck et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY